{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Ryanodine : Questions médicales les plus fréquentes",
"headline": "Ryanodine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Ryanodine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-07",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Ryanodine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pyrroles",
"url": "https://questionsmedicales.fr/mesh/D011758",
"about": {
"@type": "MedicalCondition",
"name": "Pyrroles",
"code": {
"@type": "MedicalCode",
"code": "D011758",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.578"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Ryanodine",
"alternateName": "Ryanodine",
"code": {
"@type": "MedicalCode",
"code": "D012433",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Takashi Murayama",
"url": "https://questionsmedicales.fr/author/Takashi%20Murayama",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Juntendo University School of Medicine, Tokyo, 113-8421, Japan."
}
},
{
"@type": "Person",
"name": "Nagomi Kurebayashi",
"url": "https://questionsmedicales.fr/author/Nagomi%20Kurebayashi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Juntendo University School of Medicine, Tokyo, 113-8421, Japan."
}
},
{
"@type": "Person",
"name": "Zhiguang Yuchi",
"url": "https://questionsmedicales.fr/author/Zhiguang%20Yuchi",
"affiliation": {
"@type": "Organization",
"name": "Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, Collaborative Innovation Center of Chemical Science and Engineering, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072,China."
}
},
{
"@type": "Person",
"name": "Andrew R Marks",
"url": "https://questionsmedicales.fr/author/Andrew%20R%20Marks",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Hadiatullah Hadiatullah",
"url": "https://questionsmedicales.fr/author/Hadiatullah%20Hadiatullah",
"affiliation": {
"@type": "Organization",
"name": "Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, Collaborative Innovation Center of Chemical Science and Engineering, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072,China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Remote physical activity intervention to promote physical activity and health in adolescent girls (the HERizon project): a multi-arm, pilot randomised trial.",
"datePublished": "2024-08-03",
"url": "https://questionsmedicales.fr/article/39097706",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12889-024-19664-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessing the acceptability of dried blood spot testing for HIV and STBBI among Métis people in a community driven pilot project in Alberta, Canada.",
"datePublished": "2022-12-08",
"url": "https://questionsmedicales.fr/article/36482470",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12913-022-08763-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Proactive Risk Assessment through Failure Mode and Effect Analysis (FMEA) for Perioperative Management Model of Oral Anticoagulant Therapy: A Pilot Project.",
"datePublished": "2022-12-07",
"url": "https://questionsmedicales.fr/article/36554313",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph192416430"
}
},
{
"@type": "ScholarlyArticle",
"name": "Teaching Person-Centered Care and Interprofessional Collaboration through a Virtual Mental Health World Café: A Mixed Methods IPE Pilot Project.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37319417",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/01612840.2023.2212780"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fetal Echocardiographic Z Score Pilot Project: Study Design and Impact of Gestational Age and Variable Type on Reproducibility of Measurements Within and Across Investigators.",
"datePublished": "2023-06-09",
"url": "https://questionsmedicales.fr/article/37302438",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.echo.2023.05.010"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Azoles",
"item": "https://questionsmedicales.fr/mesh/D001393"
},
{
"@type": "ListItem",
"position": 5,
"name": "Pyrroles",
"item": "https://questionsmedicales.fr/mesh/D011758"
},
{
"@type": "ListItem",
"position": 6,
"name": "Ryanodine",
"item": "https://questionsmedicales.fr/mesh/D012433"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Ryanodine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Ryanodine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Ryanodine",
"description": "Comment le ryanodine est-il utilisé dans le diagnostic médical ?\nQuels tests peuvent impliquer le ryanodine ?\nLe ryanodine aide-t-il à diagnostiquer des maladies spécifiques ?\nQuels marqueurs sont affectés par le ryanodine ?\nLe ryanodine est-il utilisé dans des études cliniques ?",
"url": "https://questionsmedicales.fr/mesh/D012433?mesh_terms=Pilot+Projects&page=7#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Ryanodine",
"description": "Quels symptômes sont associés à une dysfonction du ryanodine ?\nLe ryanodine peut-il provoquer des effets secondaires ?\nComment le ryanodine affecte-t-il le cœur ?\nY a-t-il des symptômes neurologiques liés au ryanodine ?\nLe ryanodine influence-t-il la respiration ?",
"url": "https://questionsmedicales.fr/mesh/D012433?mesh_terms=Pilot+Projects&page=7#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Ryanodine",
"description": "Comment prévenir les effets indésirables du ryanodine ?\nY a-t-il des recommandations alimentaires pour les utilisateurs de ryanodine ?\nLes patients doivent-ils éviter certains médicaments avec le ryanodine ?\nComment évaluer le risque d'effets secondaires ?\nLe suivi médical est-il important lors de l'utilisation du ryanodine ?",
"url": "https://questionsmedicales.fr/mesh/D012433?mesh_terms=Pilot+Projects&page=7#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Ryanodine",
"description": "Comment le ryanodine est-il utilisé en traitement ?\nLe ryanodine est-il administré par voie orale ?\nQuels médicaments interagissent avec le ryanodine ?\nLe ryanodine est-il utilisé en anesthésie ?\nY a-t-il des alternatives au ryanodine ?",
"url": "https://questionsmedicales.fr/mesh/D012433?mesh_terms=Pilot+Projects&page=7#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Ryanodine",
"description": "Quelles complications peuvent survenir avec le ryanodine ?\nLe ryanodine peut-il causer des dommages permanents ?\nComment gérer les complications liées au ryanodine ?\nLes complications sont-elles prévisibles ?\nLe ryanodine peut-il interagir avec d'autres traitements ?",
"url": "https://questionsmedicales.fr/mesh/D012433?mesh_terms=Pilot+Projects&page=7#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Ryanodine",
"description": "Quels sont les facteurs de risque liés au ryanodine ?\nL'âge influence-t-il les risques associés au ryanodine ?\nY a-t-il des prédispositions génétiques au ryanodine ?\nLes habitudes de vie affectent-elles les risques ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D012433?mesh_terms=Pilot+Projects&page=7#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le ryanodine est-il utilisé dans le diagnostic médical ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé pour évaluer les dysfonctionnements du calcium dans les muscles."
}
},
{
"@type": "Question",
"name": "Quels tests peuvent impliquer le ryanodine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de contraction musculaire et des études de flux calcique peuvent être réalisés."
}
},
{
"@type": "Question",
"name": "Le ryanodine aide-t-il à diagnostiquer des maladies spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut aider à diagnostiquer des myopathies liées à des anomalies du calcium."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont affectés par le ryanodine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut influencer les niveaux de calcium intracellulaire et les enzymes musculaires."
}
},
{
"@type": "Question",
"name": "Le ryanodine est-il utilisé dans des études cliniques ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est utilisé dans des études sur les troubles musculaires et cardiaques."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une dysfonction du ryanodine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des crampes musculaires, une faiblesse et des douleurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le ryanodine peut-il provoquer des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets comme des troubles de la contraction musculaire peuvent se produire."
}
},
{
"@type": "Question",
"name": "Comment le ryanodine affecte-t-il le cœur ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut provoquer des arythmies en modifiant le flux calcique dans les cardiomyocytes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques liés au ryanodine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des tremblements ou des spasmes peuvent être observés."
}
},
{
"@type": "Question",
"name": "Le ryanodine influence-t-il la respiration ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une dysfonction musculaire peut affecter les muscles respiratoires."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables du ryanodine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance médicale régulière et un ajustement de la dose sont essentiels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations alimentaires pour les utilisateurs de ryanodine ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée en calcium et en électrolytes est recommandée."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains médicaments avec le ryanodine ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les médicaments qui affectent le calcium sans avis médical."
}
},
{
"@type": "Question",
"name": "Comment évaluer le risque d'effets secondaires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests réguliers de la fonction musculaire et cardiaque sont conseillés."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il important lors de l'utilisation du ryanodine ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter rapidement les complications."
}
},
{
"@type": "Question",
"name": "Comment le ryanodine est-il utilisé en traitement ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé pour traiter certaines myopathies et troubles du calcium."
}
},
{
"@type": "Question",
"name": "Le ryanodine est-il administré par voie orale ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il est généralement administré par injection ou perfusion intraveineuse."
}
},
{
"@type": "Question",
"name": "Quels médicaments interagissent avec le ryanodine ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments affectant le calcium, comme les bloqueurs des canaux calciques, peuvent interagir."
}
},
{
"@type": "Question",
"name": "Le ryanodine est-il utilisé en anesthésie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être utilisé pour prévenir des complications musculaires pendant l'anesthésie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives au ryanodine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, d'autres agents modulant le calcium peuvent être utilisés selon les besoins."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le ryanodine ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des arythmies et des troubles musculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le ryanodine peut-il causer des dommages permanents ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dommages permanents sont rares mais possibles en cas d'utilisation prolongée."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées au ryanodine ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une intervention médicale rapide et un ajustement du traitement sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévisibles avec une surveillance adéquate."
}
},
{
"@type": "Question",
"name": "Le ryanodine peut-il interagir avec d'autres traitements ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interactions avec d'autres traitements peuvent augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque liés au ryanodine ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de troubles musculaires et cardiaques augmentent les risques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les risques associés au ryanodine ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent être plus sensibles aux effets du ryanodine."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques au ryanodine ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines conditions génétiques peuvent augmenter la sensibilité au ryanodine."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie affectent-elles les risques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme ou l'alcool peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions peuvent exacerber les effets indésirables du ryanodine."
}
}
]
}
]
}
Engaging in physical activity (PA) during adolescence is beneficial for health and positive development. However, most adolescent girls have low PA levels, and there is a need for interventions outsid...
Girls living in the UK or Ireland, aged between 13 and 16 years old, who wished to increase their activity levels, were eligible for the study. Using a random number generator, participants (n = 153; ...
Participation in the PA programme group was associated with higher perceived competence (0.6, 95% CI 0.1 to 1.2), identified regulation (0.7, 95% CI 0.2 to 1.1) and intrinsic motivation (0.9, 95% CI 0...
Results suggest perceived competence increased across all intervention arms, while the PA programme group enhanced autonomous motivation in the short term. Intervention arms with behaviour change supp...
Little literature exists on culturally grounded approaches for addressing human immunodeficiency virus (HIV) and sexually transmitted and blood-borne infections (STBBI) among Métis people. The goal of...
Grounded in community-based and Indigenous research approaches and working in partnership with a Métis community-based organization, data collection included a survey and four gathering circles with M...
Twenty-six of the 30 DBST recipients completed surveys, and 19 DBST recipients participated in gathering circles. Survey results suggest DBST is a highly acceptable STBBI testing method to Métis commu...
These findings illustrate the potential for DBST to be part of a culturally grounded, Métis-specific response to HIV and STBBI....
Correct perioperative management of anticoagulant therapy is essential to prevent thromboembolic events and reduce the risk of bleeding. The lack of universally accepted guidelines makes perioperative...
A multidisciplinary working group was set up, and four main phases of the process were identified. Each of these phases was divided into micro-activities to identify the related possible failure modes...
Seventeen failure modes were identified in the entire perioperative period; those with a higher priority of intervention concern the incorrect timing between therapy suspension and surgery, and the in...
The FMEA method can help identify anticoagulant therapy perioperative failures and implement the management and patient safety of surgical procedures....
The purpose of this convergent mixed methods interprofessional education (IPE) pilot project was to help health profession students gain valuable insight about the experiences of people living with me...
Fetal echocardiography is widely available, but normative data are not robust. In this pilot study, the authors evaluated (1) the feasibility of prespecified measurements in a normal fetal echocardiog...
Images from predefined gestational age groups (16-20, >20-24, >24-28, and >28-32 weeks) were retrospectively analyzed. Fetal echocardiography expert raters attended online group training and then inde...
Expert raters completed each set of measurements in a mean of 23 ± 9 min/fetus. Missingness ranged from 0% to 29%. CoVs were similar across age groups for all variables (P < .05) except ductus arterio...
There is considerable variability in fetal echocardiographic quantification in clinical practice that may affect the design of multicenter fetal echocardiographic Z score studies, and not all measurem...
Homelessness continues to be a pervasive public health problem throughout Canada. Hospital Emergency Departments (EDs) and inpatient wards have become a source of temporary care and shelter for homele...
Teen dating violence (TDV) is a prevalent problem in the United States. Although research indicates that prevention programs have favorable effects on TDV knowledge/attitudes, there is limited evidenc...
We evaluated the feasibility and discriminability of recently proposed Clinical Performance Measures for Neurocritical Care (Neurocritical Care Society) and Quality Indicators for Traumatic Brain Inju...
At three centers within the Collaborative Hospital Repository Uniting Standards (CHoRUS) for Equitable AI consortium, we examined consecutive neurocritical care admissions exceeding 24 h (03/2015-02/2...
A total of 14,985 admissions met inclusion criteria. ICPM was documented in 1514 (10.1%), neurologic assessments in 14,635 (91.1%), and IPCd application in 14,175 (88.5%). ICPM began within 24 h for 1...
Electronic health record-derived reporting of neurocritical care performance measures is feasible and demonstrates site-specific variation. Future efforts should examine whether performance or documen...
Environmental aspects and sustainability are becoming increasingly important. In addition to energy consumption, the consumption and environmental discharge of contrast agents pose a particular challe...
In a pilot project, a set of measures (installation of specific separation toilets, the establishment of feedback systems, interviews, questionnaires, and observation) was implemented to sensitize pat...
In the initial baseline phase, a separation toilet with an additional collection system and a feedback/button system was installed. The built-in feedback system indicated that the separation toilets w...
Measures to reduce the discharge of XCAs into the environment have a high acceptance among staff and patients. The subsequent installation of separation toilets is one possibility to achieve on-site r...
· The input of X-ray contrast agents into the environment is relevant in light of the quantity. · Measures to reduce the discharge of X-ray contrast agents into the environment have been investigated ...
· Beer M, Schuler J, Kraus E et al. Discharge of iodine-containing contrast media into the environment - problem analysis and implementation of measures to reduce discharge by means of separation toil...
This analysis presents the outcomes of the operations of the National Cancer Network (NCN) pilot project in Lower Silesian Voivodeship, Poland, for lung cancer for the period of 2019-2021. The results...
Twenty-one measures used to gauge the quality of oncological care for lung cancer were assessed. Data collection and processing for the purpose of calculating the measures were carried out as part of ...
A total of 3,638 patients diagnosed with lung cancer were enrolled in the NCN pilot program during the analysed period. For 3 measures, out of 21, target values were obtained. For 2 measures, the valu...
In our opinion, the NCN pilot study, as a test of the network's functioning, meets the assumed goal. The NCN assessment is based on, inter alia, analysis of the outcomes of oncological quality of care...